When selling equipment — whether to bring your facility up to current requirements, maximize the return from your existing footprint, or liquidate assets when closing or selling a facility — the expertise and resources of a strategic equipment management partner can optimize your resource recovery.
Mergers and acquisitions have come to define both growth and consolidation in pharmaceutical manufacturing over the last decade. Often, a merger or acquisition is the quickest, most cost-effective way to realize advanced capability without building a facility from the ground up. However, even a successful merger or acquisition of manufacturing facilities creates a range of asset management issues.
Idle pharmaceutical manufacturing and packaging equipment costs money to maintain, depreciates in value, takes up valuable footprint space, and incurs insurance costs. Selling that unused equipment can generate significant cost savings opportunities.
This article provides an overview of the trend of multiproduct and flexible facilities, defining the different types of facilities, and how working with a partner is a strategic move for any company looking to achieve an internal update in the most cost-efficient manner possible.
Mergers and acquisitions among pharmaceutical companies, as well as an ever-changing product mix, lead to surplus capital equipment among pharmaceutical manufacturing facilities. Often these surplus inventories occupy valuable manufacturing and lab space, or they are in storage facilities or "bone yards." An effective capital equipment investment recovery strategy can help turn idled equipment into money-making assets.
All manufacturing organizations need to responsibly manage assets, but pharmaceutical equipment requires unique strategies to manage and recapture its value. This article is the second of a two-part article discussing the unique value proposition of used pharmaceutical manufacturing equipment.